New hope for kids with rare lymphoma: targeted drug combo shows promise

NCT ID NCT01516567

Completed Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Feb 13, 2026 · Last updated May 15, 2026 · Updated 16 times

Summary

This study tested a treatment called DA-EPOCH-Rituximab in 47 children and teens with a rare type of lymphoma (PMLBL). The goal was to see if this combination of chemotherapy and a targeted antibody could keep the cancer from coming back. The trial measured how long patients lived without the disease getting worse and tracked both short- and long-term side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

2nd Dept. of Pediatrics Semmelweis Univ.

Budapest, 1094, Hungary
Associazione Italiana di Ematologia ed Oncologia Pediatrica

Padova, 35128, Italy
Children Oncology Group Operations centres

Monrovia, Canada
Emma Children's Hospital

Amsterdam, 1105 AZ, Netherlands
Gustave Roussy

Villejuif, 94805, France
Rectorat of Medical University

Wroclaw, Poland
Sociedad Española de Hematología y Oncología Pediátricas

Valencia, 46010, Spain
University Hospitals Leuven

Leuven, 3000, Belgium
University of Birmingham

Birmingham, United Kingdom

Conditions

Explore the condition pages connected to this study.

PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA